Alexandria Hammond
Stock Analyst at Wolfe Research
(2.61)
# 2,103
Out of 5,116 analysts
14
Total ratings
66.67%
Success rate
13.37%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alexandria Hammond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie | Downgrades: Peer Perform | n/a | $223.01 | - | 2 | Jan 8, 2026 | |
| MRK Merck & Co. | Upgrades: Outperform | $135 | $110.27 | +22.43% | 2 | Jan 8, 2026 | |
| MDGL Madrigal Pharmaceuticals | Upgrades: Neutral | $266 → $445 | $489.31 | -9.06% | 2 | Nov 3, 2025 | |
| REGN Regeneron Pharmaceuticals | Initiates: Outperform | $1,150 | $741.45 | +55.10% | 1 | Nov 15, 2024 | |
| PFE Pfizer | Initiates: Underperform | $25 | $26.44 | -5.45% | 1 | Nov 15, 2024 | |
| MRNA Moderna | Initiates: Underperform | $40 | $44.07 | -9.24% | 1 | Nov 15, 2024 | |
| LLY Eli Lilly and Company | Initiates: Outperform | $1,000 | $1,037.15 | -3.58% | 1 | Nov 15, 2024 | |
| JNJ Johnson & Johnson | Initiates: Outperform | $190 | $227.25 | -16.39% | 1 | Nov 15, 2024 | |
| GILD Gilead Sciences | Initiates: Outperform | $110 | $141.95 | -22.51% | 1 | Nov 15, 2024 | |
| BMY Bristol-Myers Squibb Company | Initiates: Peer Perform | n/a | $55.05 | - | 1 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $179.89 | - | 1 | Nov 15, 2024 |
AbbVie
Jan 8, 2026
Downgrades: Peer Perform
Price Target: n/a
Current: $223.01
Upside: -
Merck & Co.
Jan 8, 2026
Upgrades: Outperform
Price Target: $135
Current: $110.27
Upside: +22.43%
Madrigal Pharmaceuticals
Nov 3, 2025
Upgrades: Neutral
Price Target: $266 → $445
Current: $489.31
Upside: -9.06%
Regeneron Pharmaceuticals
Nov 15, 2024
Initiates: Outperform
Price Target: $1,150
Current: $741.45
Upside: +55.10%
Pfizer
Nov 15, 2024
Initiates: Underperform
Price Target: $25
Current: $26.44
Upside: -5.45%
Moderna
Nov 15, 2024
Initiates: Underperform
Price Target: $40
Current: $44.07
Upside: -9.24%
Eli Lilly and Company
Nov 15, 2024
Initiates: Outperform
Price Target: $1,000
Current: $1,037.15
Upside: -3.58%
Johnson & Johnson
Nov 15, 2024
Initiates: Outperform
Price Target: $190
Current: $227.25
Upside: -16.39%
Gilead Sciences
Nov 15, 2024
Initiates: Outperform
Price Target: $110
Current: $141.95
Upside: -22.51%
Bristol-Myers Squibb Company
Nov 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $55.05
Upside: -
Nov 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $179.89
Upside: -